Diallyl trisulfide (DATS) ameliorates cardiac fibrosis in a rat model of diabetes

• Published in: Journal of functional foods 2023-12, Vol.111, p.105901, Article 105901
• Main Authors: Jine-Yuan Hsieh, Dennis, Ng, Shang-Chuan, Lu, Shang-Yeh, Chiu, Yen-Tun, Lin, Kuan-Ho, Lin, Yueh-Min, Huang, Chih-Yang, Kuo, Wei-Wen
• Format: Article
• Language: English
• Subjects: Diabetic mellitus (Hsieh et al.); Diallyl trisulfide (DATS); Fibrosis; NFκB; Smad2/3
• ISSN: 1756-4646
• DOI: 10.1016/j.jff.2023.105901

Cardiac fibrosis is a prevalent pathological complication observed in individuals with diabetes. Diallyl trisulfide (DATS), a bioactive compound found in garlic oil, has been reported to exhibit anti-inflammatory and anti-apoptotic effects in various cardiovascular diseases. However, its potential impact on cardiac fibrosis, particularly in the context of diabetes, remains unknown. In the neonatal rat ventricular fibroblasts (NRVFs) model, our results demonstrated that DATS effectively attenuated advanced glycation end products (AGEs)-induced activation of Nuclear factor kappa B (NF-κB) and Smad2/3 signaling pathways, leading to a reduction in the downstream secretion of pro-inflammatory cytokines and collagen synthesis. In the in vivo study using echocardiographic assessment, administration of DATS significantly ameliorated cardiac dysfunction induced by streptozotocin (STZ). Taken together, our findings highlight the potential of DATS as a promising therapeutic agent for mitigating cardiac fibrosis associated with diabetes, emphasizing its potential clinical relevance in the prevention and management of diabetic cardiomyopathy.